{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Histiocytosis%2C+Langerhans-Cell",
    "query": {
      "condition": "Histiocytosis, Langerhans-Cell"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Histiocytosis%2C+Langerhans-Cell&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:50:03.420Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01998633",
      "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "Chronic Active Epstein-Barr Virus Infection",
        "Chronic Granulomatous Disease",
        "HIGM-1",
        "Leukocyte Adhesion Deficiency",
        "IPEX"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Months to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998633"
    },
    {
      "nct_id": "NCT00618540",
      "title": "Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Histiocytosis, Langerhans-cell"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2007-01",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00618540"
    },
    {
      "nct_id": "NCT01471067",
      "title": "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blood And Marrow Transplantation",
        "Leukemia",
        "Lymphoma",
        "Transplantation Infection",
        "Transplantation, Bone Marrow"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cord Blood Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "1 Year to 80 Years"
      },
      "enrollment_count": 33,
      "start_date": "2012-07-13",
      "completion_date": "2017-04-25",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01471067"
    },
    {
      "nct_id": "NCT03233204",
      "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma",
        "Low Grade Glioma",
        "Malignant Glioma",
        "Recurrent Childhood Central Nervous System Neoplasm",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Malignant Germ Cell Tumor",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Refractory Childhood Malignant Germ Cell Tumor",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Rhabdoid Tumor",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-09-14",
      "completion_date": "2024-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 111,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233204"
    },
    {
      "nct_id": "NCT02939547",
      "title": "Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Niemann-Pick Disease, Type C1"
      ],
      "interventions": [
        {
          "name": "Hydroxypropyl-beta-cyclodextrin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyclo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2017-10-11",
      "completion_date": "2020-02-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Morristown, New Jersey",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02939547"
    },
    {
      "nct_id": "NCT02089724",
      "title": "Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Erdheim-Chester Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Groupe Hospitalier Pitie-Salpetriere",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2019-04",
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02089724"
    },
    {
      "nct_id": "NCT02285582",
      "title": "International Rare Histiocytic Disorders Registry (IRHDR)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rare Histiocytic Disorders (RHDs)",
        "Erdheim-Chester Disease (ECD)",
        "Rosai-Dorfman Disease (RDD)",
        "Xanthogranuloma Family (XG)",
        "Indeterminate Dendritic Cell Histiocytosis",
        "Malignant Histiocytic Neoplasm (MHN)",
        "ALK-positive Histiocytosis",
        "Mixed Histiocytosis (MXH)",
        "Multicentric Reticulohistiocytoma (MRH)",
        "Necrobiotic Xanthogranuloma (NX)"
      ],
      "interventions": [
        {
          "name": "Registry study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Hospital for Sick Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 400,
      "start_date": "2014-10",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Madera, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285582"
    },
    {
      "nct_id": "NCT03311854",
      "title": "A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macrophage Activation Syndrome",
        "Lymphohistiocytosis, Hemophagocytic",
        "Arthritis, Juvenile",
        "Adult Onset Still Disease"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-02-20",
      "completion_date": "2020-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311854"
    },
    {
      "nct_id": "NCT04079179",
      "title": "Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Langerhan's Cell Histiocytosis",
        "Juvenile Xanthogranuloma",
        "Erdheim-Chester Disease",
        "Rosai Dorfman Disease",
        "Neuro-Degenerative Disease",
        "Histiocytic Sarcoma",
        "Histiocytic Disorders, Malignant"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carl Allen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 90,
      "start_date": "2021-04-19",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04079179"
    },
    {
      "nct_id": "NCT02281760",
      "title": "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF V600E Mutation"
      ],
      "interventions": [
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-11-01",
      "completion_date": "2018-08-29",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-07-22T07:50:03.420Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281760"
    }
  ]
}